| Title |
Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults
|
|---|---|
| Published in |
Cochrane database of systematic reviews, June 2013
|
| DOI | 10.1002/14651858.cd010609 |
| Pubmed ID | |
| Authors |
Mattias Linde, Wim M Mulleners, Edward P Chronicle, Douglas C McCrory |
| Abstract |
Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an update of a Cochrane review first published in 2004, and previously updated (conclusions not changed) in 2007. |
X Demographics
The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 5 | 21% |
| Spain | 3 | 13% |
| United States | 3 | 13% |
| Germany | 1 | 4% |
| France | 1 | 4% |
| Grenada | 1 | 4% |
| Norway | 1 | 4% |
| Colombia | 1 | 4% |
| Unknown | 8 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 17 | 71% |
| Scientists | 4 | 17% |
| Practitioners (doctors, other healthcare professionals) | 3 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 258 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Korea, Republic of | 1 | <1% |
| Netherlands | 1 | <1% |
| Denmark | 1 | <1% |
| Unknown | 253 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 39 | 15% |
| Student > Bachelor | 33 | 13% |
| Student > Ph. D. Student | 23 | 9% |
| Researcher | 19 | 7% |
| Other | 14 | 5% |
| Other | 55 | 21% |
| Unknown | 75 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 96 | 37% |
| Nursing and Health Professions | 29 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 5% |
| Neuroscience | 10 | 4% |
| Unspecified | 6 | 2% |
| Other | 25 | 10% |
| Unknown | 80 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 October 2020.
All research outputs
#1,239,834
of 25,721,020 outputs
Outputs from Cochrane database of systematic reviews
#2,589
of 13,135 outputs
Outputs of similar age
#10,119
of 209,999 outputs
Outputs of similar age from Cochrane database of systematic reviews
#50
of 295 outputs
Altmetric has tracked 25,721,020 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,135 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,999 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 295 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.